Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Lieberman

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Biological Psychiatry|December 13, 2006
NCAM1 and neurocognition in schizophreniaPatrick F Sullivan, Richard S E Keefe, Leslie A Lange, et al.
Pharmacogenomics|August 13, 2013
Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment?Lai Fong Chan, Clement Zai, Marcellino Monda, et al.
Schizophrenia Research|September 27, 2005
Decision-making capacity for research participation among individuals in the CATIE schizophrenia trialScott Stroup, Paul Appelbaum, Marvin Swartz, et al.
Psychiatry Research|December 21, 2010
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosisVirginia L Stauffer, Michael Case, Bruce J Kinon, et al.
Journal of Clinical Pharmacology|October 22, 2009
Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smokingYuyan Jin, Bruce G Pollock, Kim Coley, et al.
Schizophrenia Research|February 22, 2011
The association between weight change and symptom reduction in the CATIE schizophrenia trialEric Hermes, Henry Nasrallah, Vicki Davis, et al.
Schizophrenia Bulletin|June 6, 2002
The Mount Sinai conference on the pharmacotherapy of schizophreniaStephen R Marder, Susan M Essock, Alexander L Miller, et al.
Journal of Clinical Psychopharmacology|May 17, 2006
Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neurolepticsKaren A Nolan, Pál Czobor, Leslie L Citrome, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 31, 2012
Finite mixture regression model analysis on antipsychotics induced weight gain: investigation of the role of the serotonergic genesBehdin Nowrouzi, Renan P Souza, Clement Zai, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 3, 2004
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disordersDiana Perkins, Jeffrey Lieberman, Hongbin Gu, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Biological Psychiatry|December 13, 2006
NCAM1 and neurocognition in schizophreniaPatrick F Sullivan, Richard S E Keefe, Leslie A Lange, et al.
Pharmacogenomics|August 13, 2013
Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment?Lai Fong Chan, Clement Zai, Marcellino Monda, et al.
Schizophrenia Research|September 27, 2005
Decision-making capacity for research participation among individuals in the CATIE schizophrenia trialScott Stroup, Paul Appelbaum, Marvin Swartz, et al.
Psychiatry Research|December 21, 2010
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosisVirginia L Stauffer, Michael Case, Bruce J Kinon, et al.
Journal of Clinical Pharmacology|October 22, 2009
Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smokingYuyan Jin, Bruce G Pollock, Kim Coley, et al.
Schizophrenia Research|February 22, 2011
The association between weight change and symptom reduction in the CATIE schizophrenia trialEric Hermes, Henry Nasrallah, Vicki Davis, et al.
Schizophrenia Bulletin|June 6, 2002
The Mount Sinai conference on the pharmacotherapy of schizophreniaStephen R Marder, Susan M Essock, Alexander L Miller, et al.
Journal of Clinical Psychopharmacology|May 17, 2006
Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neurolepticsKaren A Nolan, Pál Czobor, Leslie L Citrome, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 31, 2012
Finite mixture regression model analysis on antipsychotics induced weight gain: investigation of the role of the serotonergic genesBehdin Nowrouzi, Renan P Souza, Clement Zai, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 3, 2004
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disordersDiana Perkins, Jeffrey Lieberman, Hongbin Gu, et al.
Pageof 7